Společnost JBS Science se sídlem v Pensylvánii dnes oznámila, že obdržela cenu 3 miliony dolarů Bridge Award for Small Business Innovation Research IIB od National Cancer Institute. Společnost vyvinula první tekutý bioptický produkt, kterým je screening DNA moči na časnou rakovinu jaterních buněk (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of rakovina jater. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating nádor DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS uvedla, že spolupracovala s Jamesem Hamiltonem z Johns Hopkins University Medical Center a Hie-Won Hannem z Thomas University Hospital na pokroku ve vývoji testu moči na rakovinu jater.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
